Trovagene to Launch Analytical Validation Program for Trans-Renal KRAS Mutation Assay | GenomeWeb

Originally published May 2. Updated May 3 to include additional details of Trovagene's product commercialization plans.

Trovagene is planning to launch an analytical validation program mid-year for its trans-renal KRAS mutation detection assay to assess its ability to gauge markers in urine samples from pancreatic cancer patients.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.